Maternal use of opioid analgesics just prior to, or during the first trimester of, pregnancy increases the risk for certain congenital heart defects among offspring.
Maternal use of opioid analgesics just prior to, or during the first trimester of, pregnancy increases the risk for certain congenital heart defects among their offspring, according to the findings of a new study conducted by researchers at the CDC.
The National Birth Defects Prevention Study is an ongoing, population-based, case-control study. Two-and-a-half percent of case mothers and 2.0% of control mothers reported using opioids therapeutically during the month prior to conception or during the first
12 weeks of pregnancy.
Compared with the mothers reporting no opioid use, those who used opioids were 2.7 times more likely (95% CI, 1.1-6.3) to have a baby with conoventricular septal defects; twice as likely (95% CI, 1.2-3.6) to have a baby with atrioventricular septal defects; 2.4 times as likely (95% CI, 1.4-4.1) to have a baby with hypoplastic left heart syndrome; twice as likely (95% CI, 1.3-3.2) to have a baby with spina bifida; and 1.8 times as likely (95% CI, 1.1-2.9) to have a baby with gastroschisis.
Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(4):314.e1-314.e11.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More